JPRN-UMIN000035660已完成未知
The impact of Dapagliflozin on epicardial fat volume - Effects of Dapagliflozin on Body Composition
Tachikawa general hospital0 个研究点目标入组 40 人开始时间: 2019年1月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •age > 75 years insulin therapy atrial fibrillation renal insufficiency (estimated glomerular filtration rate < 45 mL/min/1.73 m2) chronic inflammatory disease coronary artery bypass graft surgery.
研究者
相似试验
已完成
4 期
Dapagliflozin Effects on Epicardial FatType 2 DiabetesNCT02235298University of Miami100
已完成
不适用
The effect of luseogliflozin on epicardial fat accumulation in obese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000019072kyo Medical and Dental University20
招募中
3 期
Effect of Dapagliflozin for Epicardial Adipose Tissue Reduction in Patients with Asymptomatic Heart FailureHeart failureAsymptomatic heart failureJPRN-jRCT1051220025Tanaka Atsushi230
进行中（未招募）
1 期
Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fractioheart failure with left ventricular ejection fraction <50%MedDRA version: 20.0Level: LLTClassification code 10024102Term: Left cardiac failureSystem Organ Class: 100000004849EUCTR2021-005394-66-ITAZIENDA OSPEDALIERA UNIVERSITARIA SENESE88
已完成
3 期
DECLARE-TIMI58JPRN-jRCT2080222423AstraZeneca KK17,150